LP therapy demonstrated clinical activity in nonendometrioid carcinoma, including rare subtypes such as carcinosarcoma and mesonephric-like adenocarcinoma. Further accumulation of patients is warranted to validate its efficacy in these uncommon histologic types.
Takahashi et al. (Mon,) studied this question.